HOWL
Werewolf Therapeutics, Inc.
Price Chart
Latest Quote
$0.37
+0.01 (+3.57%)
Current Price
| Previous Close | $0.36 |
| Open | $0.35 |
| Day High | $0.38 |
| Day Low | $0.35 |
| Volume | 803,903 |
Stock Information
| Shares Outstanding | 48.60M |
| Total Debt | $37.65M |
| Cash Equivalents | $46.45M |
| Net Income | $-56.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $18.20M |
| EPS (TTM) | $-1.21 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.78M |
| Income | $-56.27M |
| Book/sh | $0.25 |
| Cash/sh | $0.96 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 1.21 |
| Current Ratio | 1.26 |
| Debt/Eq | 308.56 |
Returns & Margins
| ROA | -39.07% |
| ROE | -161.89% |
Ownership
| Insider Ownership | 5.61% |
| Institutional Ownership | 30.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.38 |
| P/B | 1.49 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $7.00 |
Technical Indicators
| SMA20 | $0.40 |
| SMA50 | $0.58 |
| SMA200 | $0.92 |
| RSI | 38.67 |
| ATR | 0.0369 |
| Shares Float | 42.93M |
| Short Float | 2.36% |
| Short Ratio | 1.48 |
| Volatility | 0.27 |
| Rel Volume | 1.24 |
Performance History
| Week | +4.06% |
| Month | -15.63% |
| Quarter | -51.35% |
| 6 Months | -45.47% |
| YTD | -41.92% |
| Year | -70.03% |
| 3 Years | -88.26% |
| 5 Years | -97.26% |
| 10 Years | -97.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.37 | 803,903 |
| 2026-06-23 | $0.36 | 515,600 |
| 2026-06-22 | $0.37 | 652,400 |
| 2026-06-18 | $0.35 | 1,575,700 |
| 2026-06-17 | $0.34 | 2,034,100 |
| 2026-06-16 | $0.36 | 584,400 |
| 2026-06-15 | $0.39 | 345,800 |
| 2026-06-12 | $0.38 | 426,000 |
| 2026-06-11 | $0.39 | 809,300 |
| 2026-06-10 | $0.37 | 171,600 |
| 2026-06-09 | $0.38 | 1,125,500 |
| 2026-06-08 | $0.38 | 694,500 |
| 2026-06-05 | $0.39 | 580,500 |
| 2026-06-04 | $0.43 | 210,800 |
| 2026-06-03 | $0.42 | 376,200 |
| 2026-06-02 | $0.43 | 388,900 |
| 2026-06-01 | $0.47 | 430,200 |
| 2026-05-29 | $0.45 | 278,900 |
| 2026-05-28 | $0.46 | 543,400 |
| 2026-05-27 | $0.49 | 396,500 |
| 2026-05-26 | $0.46 | 797,900 |
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
đ° Latest News
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation
Simply Wall St. âĸ 2026-05-14T11:23:19Z
Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results
Insider Monkey âĸ 2026-01-13T14:56:47Z
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2025-12-15T17:00:04Z
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
Zacks âĸ 2025-10-31T12:58:00Z
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
Zacks âĸ 2025-10-29T17:45:00Z
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
Zacks âĸ 2025-10-28T18:26:00Z
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
Zacks âĸ 2025-10-23T18:54:00Z
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Zacks âĸ 2025-10-23T16:00:04Z
3 Promising Penny Stocks With Market Caps Under $700M
Simply Wall St. âĸ 2025-09-25T18:05:26Z
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
Zacks âĸ 2025-09-08T21:03:46Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $1,885,000 | $19,943,000 | $16,401,000 |
| Operating Revenue | $0 | $1,885,000 | $19,943,000 | $16,401,000 |
| Expenses | ||||
| Interest Expense | $5,274,000 | $4,656,000 | $3,139,000 | $0 |
| Total Expenses | $60,677,000 | $75,479,000 | $60,446,000 | $72,457,000 |
| Other Income Expense | $2,021,000 | $1,062,000 | $-1,142,000 | $338,000 |
| Other Non Operating Income Expenses | $2,021,000 | $1,615,000 | $-1,142,000 | $338,000 |
| Net Non Operating Interest Income Expense | $-2,166,000 | $2,017,000 | $4,277,000 | $1,908,000 |
| Interest Expense Non Operating | $5,274,000 | $4,656,000 | $3,139,000 | $0 |
| Operating Expense | $60,677,000 | $75,479,000 | $60,446,000 | $72,457,000 |
| General And Administrative Expense | $15,847,000 | $19,045,000 | $18,670,000 | $18,696,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Net Interest Income | $-2,166,000 | $2,017,000 | $4,277,000 | $1,908,000 |
| Interest Income | $3,108,000 | $6,673,000 | $7,416,000 | $1,908,000 |
| Normalized Income | $-60,822,000 | $-69,962,000 | $-37,368,000 | $-53,810,000 |
| Net Income From Continuing And Discontinued Operation | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Total Operating Income As Reported | $-60,677,000 | $-73,594,000 | $-40,503,000 | $-56,056,000 |
| Net Income Common Stockholders | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Net Income | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Net Income Including Noncontrolling Interests | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Net Income Continuous Operations | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Pretax Income | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Special Income Charges | $0 | $-553,000 | $0 | - |
| Interest Income Non Operating | $3,108,000 | $6,673,000 | $7,416,000 | $1,908,000 |
| Operating Income | $-60,677,000 | $-73,594,000 | $-40,503,000 | $-56,056,000 |
| Per Share | ||||
| Diluted EPS | $-1.33 | $-1.63 | $-1.05 | $-1.86 |
| Basic EPS | $-1.32 | $-1.63 | $-1.05 | $-1.86 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-53,914,000 | $-63,492,000 | $-32,465,000 | $-52,706,000 |
| Total Unusual Items | $0 | $-553,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-553,000 | $0 | - |
| Reconciled Depreciation | $1,634,000 | $1,814,000 | $1,764,000 | $1,104,000 |
| EBITDA (Bullshit earnings) | $-53,914,000 | $-64,045,000 | $-32,465,000 | $-52,706,000 |
| EBIT | $-55,548,000 | $-65,859,000 | $-34,229,000 | $-53,810,000 |
| Diluted Average Shares | $46,810,252 | $43,859,664 | $35,646,572 | $28,864,000 |
| Basic Average Shares | $46,018,888 | $43,332,088 | $35,646,572 | $28,864,000 |
| Diluted NI Availto Com Stockholders | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Research And Development | $44,830,000 | $56,434,000 | $41,776,000 | $53,761,000 |
| Selling General And Administration | $15,847,000 | $19,045,000 | $18,670,000 | $18,696,000 |
| Other Gand A | $7,423,000 | $8,249,000 | $7,703,000 | $6,895,000 |
| Insurance And Claims | $1,065,000 | $1,151,000 | $1,780,000 | $2,852,000 |
| Salaries And Wages | $7,359,000 | $9,645,000 | $9,187,000 | $8,949,000 |
| Other Special Charges | - | $553,000 | - | - |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $24,805,000 | $73,390,000 | $111,374,000 | $122,337,000 |
| Total Assets | $69,396,000 | $126,929,000 | $174,833,000 | $160,245,000 |
| Total Non Current Assets | $10,810,000 | $13,863,000 | $36,463,000 | $20,045,000 |
| Other Non Current Assets | $906,000 | $1,540,000 | $21,617,000 | $2,594,000 |
| Current Assets | $58,586,000 | $113,066,000 | $138,370,000 | $140,200,000 |
| Other Current Assets | $1,536,000 | $2,071,000 | $2,677,000 | $3,957,000 |
| Cash Cash Equivalents And Short Term Investments | $57,050,000 | $110,995,000 | $134,343,000 | $129,315,000 |
| Cash And Cash Equivalents | $57,050,000 | $110,995,000 | $134,343,000 | $129,315,000 |
| Receivables | - | $0 | $1,350,000 | $6,928,000 |
| Other Receivables | - | - | $1,350,000 | $6,928,000 |
| Non Current Deferred Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $37,671,000 | $37,087,000 | $51,923,000 | $14,684,000 |
| Long Term Debt And Capital Lease Obligation | $7,684,000 | $35,530,000 | $43,648,000 | $12,600,000 |
| Current Debt And Capital Lease Obligation | $29,987,000 | $1,557,000 | $8,275,000 | $2,084,000 |
| Current Debt | $28,236,000 | - | $6,667,000 | - |
| Other Current Borrowings | $28,236,000 | - | $6,667,000 | - |
| Long Term Debt | - | $26,095,000 | $32,656,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $44,591,000 | $53,539,000 | $63,459,000 | $37,908,000 |
| Total Non Current Liabilities Net Minority Interest | $8,443,000 | $38,359,000 | $44,081,000 | $13,919,000 |
| Derivative Product Liabilities | $759,000 | $2,829,000 | $0 | - |
| Current Liabilities | $36,148,000 | $15,180,000 | $19,378,000 | $23,989,000 |
| Payables And Accrued Expenses | $5,859,000 | $10,007,000 | $6,569,000 | $11,668,000 |
| Interest Payable | $266,000 | $266,000 | $310,000 | $0 |
| Payables | $754,000 | $3,035,000 | $1,336,000 | $1,221,000 |
| Accounts Payable | $754,000 | $3,035,000 | $1,336,000 | $1,221,000 |
| Non Current Deferred Liabilities | - | $0 | $433,000 | $1,128,000 |
| Current Deferred Liabilities | - | $0 | $907,000 | $6,532,000 |
| Other Non Current Liabilities | - | - | - | $191,000 |
| Other Current Liabilities | - | - | - | $570,000 |
| Equity | ||||
| Common Stock Equity | $24,805,000 | $73,390,000 | $111,374,000 | $122,337,000 |
| Total Equity Gross Minority Interest | $24,805,000 | $73,390,000 | $111,374,000 | $122,337,000 |
| Stockholders Equity | $24,805,000 | $73,390,000 | $111,374,000 | $122,337,000 |
| Retained Earnings | $-475,410,000 | $-414,588,000 | $-344,073,000 | $-306,705,000 |
| Other | ||||
| Ordinary Shares Number | $48,596,817 | $44,827,159 | $39,107,048 | $31,434,000 |
| Share Issued | $48,596,817 | $44,827,159 | $39,107,048 | $31,434,000 |
| Tangible Book Value | $24,805,000 | $73,390,000 | $111,374,000 | $122,337,000 |
| Invested Capital | $53,041,000 | $99,485,000 | $150,697,000 | $122,337,000 |
| Working Capital | $22,438,000 | $97,886,000 | $118,992,000 | $116,211,000 |
| Capital Lease Obligations | $9,435,000 | $10,992,000 | $12,600,000 | $14,684,000 |
| Total Capitalization | $24,805,000 | $99,485,000 | $144,030,000 | $122,337,000 |
| Additional Paid In Capital | $500,210,000 | $487,973,000 | $455,443,000 | $429,039,000 |
| Capital Stock | $5,000 | $5,000 | $4,000 | $3,000 |
| Common Stock | $5,000 | $5,000 | $4,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $7,684,000 | $9,435,000 | $10,992,000 | $12,600,000 |
| Current Capital Lease Obligation | $1,751,000 | $1,557,000 | $1,608,000 | $2,084,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $302,000 | $3,616,000 | $3,627,000 | $3,135,000 |
| Current Accrued Expenses | $5,105,000 | $6,972,000 | $5,233,000 | $10,447,000 |
| Net PPE | $9,904,000 | $12,323,000 | $14,846,000 | $17,451,000 |
| Accumulated Depreciation | $-6,618,000 | $-4,984,000 | $-3,170,000 | $-1,406,000 |
| Gross PPE | $16,522,000 | $17,307,000 | $18,016,000 | $18,857,000 |
| Leases | $7,971,000 | $7,971,000 | $7,971,000 | $7,971,000 |
| Other Properties | $7,701,000 | $8,486,000 | $9,227,000 | $10,098,000 |
| Machinery Furniture Equipment | $850,000 | $850,000 | $818,000 | $682,000 |
| Properties | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | - | $0 | $433,000 | $1,128,000 |
| Current Deferred Revenue | - | $0 | $907,000 | $6,532,000 |
| Treasury Shares Number | - | - | $0 | - |
| Construction In Progress | - | - | $0 | $106,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-60,292,000 | $-56,442,000 | $-33,381,000 | $-44,207,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-60,292,000 | $-56,188,000 | $-32,612,000 | $-40,596,000 |
| Cash Flow From Continuing Operating Activities | $-60,292,000 | $-56,188,000 | $-32,612,000 | $-40,596,000 |
| Operating Gains Losses | $-2,070,000 | $-1,068,000 | - | $7,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-254,000 | $-769,000 | $-3,611,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-254,000 | $-769,000 | $-3,611,000 |
| Capital Expenditure | - | $-254,000 | $-769,000 | $-3,611,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,939,000 | $23,576,000 | $18,329,000 | $15,740,000 |
| Financing Cash Flow | $6,028,000 | $13,080,000 | $58,429,000 | $15,906,000 |
| Cash Flow From Continuing Financing Activities | $6,028,000 | $13,080,000 | $58,429,000 | $15,906,000 |
| Net Common Stock Issuance | $5,939,000 | $23,576,000 | $18,329,000 | $15,740,000 |
| Common Stock Issuance | $5,939,000 | $23,576,000 | $18,329,000 | $15,740,000 |
| Net Other Financing Charges | - | $-673,000 | - | $-88,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-40,000,000 | $0 | - |
| Issuance Of Debt | $0 | $30,000,000 | $40,000,000 | $0 |
| Interest Paid Supplemental Data | $3,133,000 | $3,358,000 | $2,556,000 | $0 |
| End Cash Position | $57,951,000 | $112,215,000 | $155,577,000 | $130,529,000 |
| Beginning Cash Position | $112,215,000 | $155,577,000 | $130,529,000 | $158,830,000 |
| Changes In Cash | $-54,264,000 | $-43,362,000 | $25,048,000 | $-28,301,000 |
| Proceeds From Stock Option Exercised | $89,000 | $177,000 | $100,000 | $254,000 |
| Net Issuance Payments Of Debt | $0 | $-10,000,000 | $40,000,000 | $0 |
| Net Long Term Debt Issuance | $0 | $-10,000,000 | $40,000,000 | $0 |
| Long Term Debt Payments | $0 | $-40,000,000 | $0 | - |
| Long Term Debt Issuance | $0 | $30,000,000 | $40,000,000 | $0 |
| Net PPE Purchase And Sale | $0 | $-254,000 | $-769,000 | $-3,611,000 |
| Purchase Of PPE | $0 | $-254,000 | $-769,000 | $-3,611,000 |
| Change In Working Capital | $-8,205,000 | $2,526,000 | $-5,894,000 | $2,539,000 |
| Change In Other Current Liabilities | $-1,557,000 | $-1,608,000 | $-2,084,000 | $191,000 |
| Change In Payables And Accrued Expense | $-7,498,000 | $3,455,000 | $-4,335,000 | $3,046,000 |
| Change In Payable | $-7,498,000 | $3,455,000 | $-4,335,000 | $3,046,000 |
| Change In Account Payable | $-7,498,000 | $3,455,000 | $-4,335,000 | $3,046,000 |
| Change In Prepaid Assets | $850,000 | $669,000 | $1,267,000 | $-262,000 |
| Change In Receivables | $0 | $1,350,000 | $5,578,000 | $-6,928,000 |
| Other Non Cash Items | $2,926,000 | $2,229,000 | $878,000 | $2,164,000 |
| Stock Based Compensation | $6,245,000 | $8,826,000 | $8,008,000 | $7,400,000 |
| Depreciation Amortization Depletion | $1,634,000 | $1,814,000 | $1,764,000 | $1,104,000 |
| Depreciation And Amortization | $1,634,000 | $1,814,000 | $1,764,000 | $1,104,000 |
| Depreciation | $1,634,000 | $1,814,000 | $1,764,000 | $1,104,000 |
| Gain Loss On Investment Securities | $-2,070,000 | $-1,621,000 | - | - |
| Net Income From Continuing Operations | $-60,822,000 | $-70,515,000 | $-37,368,000 | $-53,810,000 |
| Change In Other Working Capital | - | $-1,340,000 | $-6,320,000 | $6,683,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $7,000 |
| Change In Other Current Assets | - | - | - | $279,000 |
| Change In Accrued Expense | - | - | - | $3,738,000 |
Fetched: 2026-06-23